Company intelligence / Profile preview
Pharmacyclics
Sunnyvale, California, United Statespharmacyclics.com ↗
- Ownership
- Public · ABBV
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Pharmacyclics developed Imbruvica® (ibrutinib), a first-in-class oral BTK inhibitor that became a blockbuster therapy for several hematological cancers. The company achieved rapid revenue growth following FDA approvals and was acquired by AbbVie in one of the largest biotech deals in history. At the time of acquisition, Imbruvica had multiple approved indications and an extensive clinical development program exploring further uses[3][6].
- Therapeutic areas
- Oncology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Janssen Biotech/Johnson & Johnson
Beyond the preview
Go deeper on Pharmacyclics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmacyclics.